CJC-1295 vs MK-677
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Phase 2 |
| Category | Growth Hormone | Growth Hormone |
| Primary Use | Growth hormone optimization and anti-aging | Growth hormone optimization and muscle growth |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 1-2mg twice weekly (with DAC) | 10-25mg daily |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Moderate |
| Clinical Trial Phase | N/A | Phase 2 |
Key Differences
- 1CJC-1295 is generally more affordable ($35 - $70/mo) compared to MK-677 ($50 - $100/mo).
- 2CJC-1295 is administered via subcutaneous injection, while MK-677 uses oral.
- 3CJC-1295 is dosed twice weekly, while MK-677 is daily.
- 4MK-677 has moderate-quality evidence, while CJC-1295 has emerging-quality evidence.
Which Is Better For...
CJC-1295
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
CJC-1295
Fewer commonly reported side effects
MK-677
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.